Emily Mrig, PhD

Assistant Adjunct Professor
David Schmidt
Phone: +1 415 514-8369
490 Illinois Street, Rm 32N
UCSF Box 0613
San Francisco, CA 94158
United States

What I do

I am a member of the Center for Translational and Policy Research on Precision Medicine (TRANSPERS). I am interested in the ways that insurance coverage and health policy shape differential access and uptake of precision medicine. I am particularly interested in applying my research towards efforts aimed at diversifying the population of people who can realize the benefits of these new health technologies.

Departmental research area

My research expertise

health services research, health policy, insurance coverage and reimbursement, precision medicine, genetic testing, targeted therapies, Oncology, hereditary conditions, palliative and hospice care, end-of-life, medical decision making, mixed-methods, observational fieldwork, all-payer claims data analysis, census data, in-depth interviewing, social science theory, public health theory

Clinical expertise

genetic testing, targeted therapies, hereditary conditions

Professional background


Dr. Emily Hammad Mrig is an Assistant Professor in the Department of Clinical Pharmacy and in the Center for Translational and Policy Research on Precision Medicine (TRANSPERS) and an affiliate faculty member at IHPS. Prior to joining the UCSF faculty, Emily completed a postdoctoral fellowship in the Department of Health Policy and Management at the Yale University School of Public Health. Emily is an interdisciplinary scholar with diverse training and experience in public health, health policy and social science that she applies to investigating inequities in access to health care, especially in the context of precision medicine, cancer, and end-of-life care. Her research engages qualitative and quantitative approaches that integrate diverse perspectives on key health policy and insurance coverage issues to promote equitable access to health and healthcare. Current projects include an investigation of barriers to genomic medicine among individuals with hereditary conditions and an examination of state-based consumer assistance programs.